Nilvadipine - Archer Pharmaceuticals
Alternative Names: ARC 029Latest Information Update: 02 Aug 2019
Price :
$50 *
At a glance
- Originator Archer Pharmaceuticals
- Class Antidementias; Antihypertensives; Dihydropyridines; Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Alzheimer's disease
Most Recent Events
- 02 Aug 2019 Phase III development is ongoing in
- 02 Aug 2019 Phase-III development is ongoing France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Sweden and United Kingdom
- 08 Jun 2018 Pharmacodynamics data from the phase III NIVALD trial in Alzheimer's disease presented at the 28th European Meeting on Hypertension and Cardiovascular Protection (ESH-2018)